Formiga Pérez, FrancescGarcia Pavia, PabloMartín Sánchez, Francisco JavierNavarro-Ruiz, AndrésRubio-Terrés, CarlosPeral, CarmenTarilonte, PatriciaLópez-Ibáñez de Aldecoa, AlejandraRubio-Rodríguez, Darío2021-06-152021-06-152011-06-111473-7167https://hdl.handle.net/2445/178415Objective: to estimate the health and economic impact of the reduction in mortality and cardiovascular hospitalizations, associated with correct diagnosis of cardiac transthyretin amyloidosis (ATTR-CM), from the Spanish National Health System (NHS) perspective. Methods: a costs and effects analysis were performed (probabilistic Markov model) with time horizons between 1 and 15 years, comparing the correct diagnosis of ATTR-CM versus the non-diagnosis. Transition probabilities were obtained from the ATTR-ACT study (placebo arm) and from the literature. Costs and healthcare resources were obtained from Spanish sources ( 2019) and from a panel of Spanish clinical experts. Results: after 1, 5, 10 and 15 years, the diagnosis of ATTR-CM would generate a gain of 0.031 (95%CI 0.025; 0.038); 0.387 (95%CI 0.329; 0.435); 0.754 (95%CI 0.678; 0.781) and 0.944 (95%CI 0.905; 0.983) life years per patient, respectively, with savings of 212 (95%CI -632; 633), 2,289 (95%CI 2,250; 2,517), 2,859 (95%CI 2,584; 3,149) and 2,906 (95%CI 2,669; 3,450) per patient, respectively, versus the non-diagnosis. Conclusions: just by correctly diagnosing ATTR-CM, years of life would be gained, cardiovascular hospitalizations would be avoided, and savings would be generated for the NHS, compared to the non-diagnosis of the disease.7 p.application/pdfengcc by nc nd (c) Formiga Pérez, Francesc et al, 2011http://creativecommons.org/licenses/by-nc-nd/4.0/AmiloïdosiDiagnòsticEspanyaAmyloidosisDiagnosisSpaininfo:eu-repo/semantics/article7127532021-06-15info:eu-repo/semantics/openAccess34047214